Abstract: Various examples are directed to systems and methods of using a database management system (DBMS) to post a transaction. An enterprise resource planning (ERP) application may receive first transaction data associated with a first transaction including acquisition of a first component of a first component type. The first transaction data may describe an indicator of the first component, a cost of the first component of a first component type, and a first environmental metric associated with the first component. The ERP application may write a first transaction entry to a universal journal table of the DBMS, the first transaction entry comprising a description of the first transaction, and a component breakdown key. The ERP application may also write a first component breakdown entry to a component breakdown table of the DBMS.

Abstract: Compounds of Formula (I): wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring anti-apoptotic inhibitors.

Abstract: The present invention relates to the identification of the xcv-1 gene, which is responsible for a recessive resistance to Xanthomonas euvesicatoria, by genetic mapping-based cloning from Capsicum annuum. In addition, the invention relates to methods for generating plants resistant to an abiotic or biotic factor, in particular to Xanthomonas euvesicatoria, and the plants themselves, in particular tomato plants.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

Abstract: Compounds of formula (I): wherein R1, R2, R5, R6, R7, R12, X, Y, A, E and n are as defined in the description. Medicinal products containing the same which are useful in treating a condition requiring a pro-apoptotic agent.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Provided is a master printed circuit board (PCB). The master PCB includes panels defined by grooves cut in the master PCB, the grooves separating one panel from another. A final PCB is formable via use of one or more jumpers, wherein the jumpers are configured to extend across at least one of the grooves to electrically connect one panel to another panel. The electrically connected panels form the final PCB.

Abstract: Compounds of formula (I): wherein R1, R2, R5, R6, R7, R12, X, Y, A, E and n are as defined in the description. Medicinal products containing the same which are useful in treating a condition requiring a pro-apoptotic agent.

Abstract: The invention is a cooling system comprising adjacent cooling deltas (21, 31) being cooled by a cooling air and being arranged along a path (20, 30). The cooling system is characterized by comprising cooling deltas (21, 31) arranged in groups (22), the cooling deltas of a group (22) being arranged essentially in the same orientation and define an essentially straight path-section, wherein the path-sections of adjacent groups (22) form a zigzagged path (20, 30).

Abstract: Compounds of formula (I); wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

Abstract: The invention is a hybrid condenser having a direct contact condenser segment (9) and a surface condenser segment (10) arranged in a common condensation space. The hybrid condenser includes a surface condenser segment (10) arranged downstream the direct contact condenser segment (9) in the direction of steam flow or below the direct contact condenser segment (9), and a water guiding element (17) ensuring that the cooling water and condensate mixture generated in the direct contact condenser segment (9) flows downward avoiding the surface condenser segment (10).

Abstract: Provided is a master printed circuit board (PCB). The master PCB includes panels defined by grooves cut in the master PCB, the grooves separating one panel from another. A final PCB is formable via use of one or more jumpers, wherein the jumpers are configured to extend across at least one of the grooves to electrically connect one panel to another panel. The electrically connected panels form the final PCB.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: The present invention relates to the identification of the xcv-1 gene, which is responsible for a recessive resistance to Xanthomonas euvesicatoria, by genetic mapping-based cloning from Capsicum annuum. In addition, the invention relates to methods for generating plants resistant to an abiotic or biotic factor, in particular to Xanthomonas euvesicatoria, and the plants themselves, in particular tomato plants.